Shaanxi Fujie Pharmaceutical Co.,ltd has been extracting licorice roots since our founding in 1993. With over 20 years of continuous experience,we have become one of the leading suppliers in the natural licorice extracts pharmaceutical industry in China.
Fujie Pharmaceuticals owns full sets of licorice industry chains including licorice import, wild licorice conservation, artificial licorice planting and production of licorice Glycyrrhizic salt and its secondary products and licorice bio-organic fertilizer.
Today, Fujie Pharmaceuticals has been one of the top producers of natural licorice extracts products in China, such as: Enoxolone(18β-Glycyrrhetinic Acid),Mono Ammonium Glycyrrhizinate(MAG),Stearyl Glycyrrhetinate,Glycyrrhizic acid A,Glabridin,Dipotassium Glycyrrhetate,Licorice Extract Liquid etc.
Fujie pharm has passed GMP,we have a professional R&D team that can customize products according to customer's needs.
more >
Year of Establishment:
1993
Total Assets(USD):
less than 500,000
Total Number of Staff:
Main Competitive Advantages:
Delivery Term,Small Orders Accepted,Quality Service
Other Competitive Advantages:
1. All production lines have passed GMP certification. The API ammonium glycyrrhizinate was certified by CEP
2. There is a stable licorice raw material base
3. The three domestic and foreign licorice bases provide raw materials directly.
Patents and Copyrights:
There are 2 invention patents, 24 utility model patents, and 5 invention patents under review.
Business Type:
Manufacturer
R&D capacity:
Own Brand
Annual Turnover(USD):
less than 500,000
Main Sales Markets:
North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Other Competitive Advantages:
1. All production lines have passed GMP certification. The API ammonium glycyrrhizinate was certified by CEP
2. There is a stable licorice raw material base
3. The three domestic and foreign licorice bases provide raw materials directly.
Patents and Copyrights:
There are 2 invention patents, 24 utility model patents, and 5 invention patents under review.